Participants Assessments
|
Pre-screen
|
Visit 1: Baseline
|
Randomisation
|
Visit 2: 4 week Follow-up
|
Visit 3: Late Pregnancy/Postnatal Follow-up
|
Visit 4: Validation of smoking status
|
---|
Trial Unit (PS)
|
X
| | | | | |
Acute Unit (PS)
|
X
| | | | | |
Consenta,b
|
X
| | | | |
X
|
Visit Datesc
| |
X
| |
X
|
X
|
X
|
Demographics/Education
| |
X
| | | | |
Smoking Behaviour 1
| |
X
| | | | |
Smoking Behaviour 2
| |
X
| | | | |
Smoking Behaviour 3
| | | | | |
X
|
Smoking Beliefs
| |
X
| | |
X
| |
Pregnancy
| |
X
| | | | |
Relationship Status
| |
X
| | | | |
Eligibility Criteria Check
| |
X
| | | | |
EQ-5D-3 Ld
| |
X
| |
X
|
X
| |
Allocation - MiQuit/Control
| | |
X
| | | |
Abstinence Check
| | | |
X
| | |
Stop Smoking Strategy/Quit attempts
| | | | |
X
| |
Attitude to Intervention (MiQuit only)e
| | | | |
X
| |
Assessment of Tobacco Exposuref
| | | | | |
X
|
- aTelephone and written consent will be performed at Pre-screening.
- bWritten consent for cotinine sample collection will be performed at V4 for those who provided telephone consent at pre-screening.
- cTelephone/face to face visit will be performed at V1 (only) and face to face/postal visit will be performed at V4 (only). Visits 2 and 3 will be telephone, with questionnaires sent to any who cannot be contacted.
- dEQ-5D-3 L - European Quality of life Five Dimension, Three Levels questionnaire to be completed by the participant.
- eA small number of those who are allocated to the MiQuit group and consent at baseline will be contacted for a qualitative telephone interview to provide feedback on their experience of the study and intervention.
- fMeasured with saliva cotinine and/or exhaled CO levels.